COMMUNIQUÉS West-GlobeNewswire

The Best Natural Testosterone Booster Supplements For Men:~ Honest Customer Reviews 2025
22/04/2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Low testosterone levels can cause many problems in men, such as less muscle, less energy, less libido and low mood. You may want to find a solution, but you don’t know which [...]
BlueGenes Partners with Level Care to Revolutionize Medication Management for Union Members
22/04/2025
SCOTTSDALE, Ariz., April 22, 2025 (GLOBE NEWSWIRE) -- BlueGenes , a pioneering technology company specializing in permission medicine, today announced a strategic partnership with Level Care, the healthcare division of [...]
Theranica Announces Coverage Policy from the Second Largest U.S. Health Insurer for Its Nerivio® REN Wearable Migraine Treatment, Reaching Access for 80 Million Americans
22/04/2025
The policy expands access to this effective, non-drug treatment for members as young as 8 years old who are diagnosed with migraine BRIDGEWATER, N.J. and NETANYA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- Theranica , a [...]
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.
22/04/2025
TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, [...]
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
22/04/2025
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a [...]
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
22/04/2025
Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume [...]
Cronos Unveils New Spinach® 1.2g Vapes and SOURZ by Spinach® Gummies Enhanced with Rare Cannabinoids
22/04/2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.’s (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, [...]
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
22/04/2025
Novel CAR design selectively targets malignant cells for patients with relapsed/refractory CD5-positive hematological diseases HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging [...]
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
22/04/2025
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first [...]
InnovAge to Announce Fiscal Third Quarter 2025 Financial Results and Host Conference Call Tuesday, May 6, 2025
22/04/2025
DENVER, April 22, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
22/04/2025
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Best Female Libido Boosters 2025 and Sexual Enhancement Pills for Women - By Oh Yes
22/04/2025
Rhyl, Wales, April 22, 2025 (GLOBE NEWSWIRE) -- A healthy sex life plays an important role in a woman's relationships, mental health, and confidence. However, nearly 1 in 3 women have sexual problems that can erode [...]
Aveanna to Participate at the Bank of America Securities 2025 Health Care Conference
22/04/2025
ATLANTA, April 22, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Bank of America Securities 2025 Health Care Conference in [...]
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
22/04/2025
Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT ™ plus immune check point inhibitor in metastatic breast cancer (MBC) 54 clinical sites across 15 states currently enrolling patients including [...]
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
22/04/2025
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it [...]
Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
22/04/2025
Fifth issued patent in the U.S. for QTORIN™ rapamycin with anticipated patent life extending into 2038 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care for microcystic lymphatic [...]
Transactions in Connection with Share Buy-back Program
22/04/2025
Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce [...]
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference
22/04/2025
CHASKA, Minn., April 22, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
22/04/2025
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel [...]

Pages